Does induction of aggrecanase 1 ( ADAM-TS4 ) by interleukin-1 occur through activation of constitutively produced protein?
These data support the hypothesis that ADAM-TS4 is constitutively produced in these cells and tissue, and that stimulation by IL-1 results in aggrecanase activation. Thus, the activator could be a potential target by which to control aggrecanase-mediated degradation in arthritic diseases.
US facilitates thrombolysis of platelet-rich thrombi and could be a useful component of thrombolytic therapy following AMI.